
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell is a medical technology company that has developed the Ceribell System, a point-of-care EEG platform that uses artificial intelligence to rapidly diagnose and monitor neurological conditions. The company recently received FDA approval for its delirium monitoring solution, and is also exploring new indications such as ischemic stroke. With a healthy financial profile and a strong pipeline, CeriBell is well-positioned for long-term growth and has the potential to become a leader in the medical technology industry.
Bears say
CeriBell is a MedTech company with a Buy rating, but there are risks to consider such as geopolitical tensions and potential tariffs that could negatively impact the company's gross margins. While the Ceribell System has gained commercial traction and the company has a healthy financial profile, it is still in the early stages of commercialization and faces competition in the market. Additionally, the company's future growth is heavily reliant on its ability to gain new accounts and maintain utilization at existing accounts.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares